Generic Biologics: European-Style Regulation Is The Answer, Big Pharma Says
Executive Summary
The Senate Health Committee hearing on developing an approval pathway for generic biologics put the brand-name pharmaceutical industry in the unusual position of advocating that Congress adopt a European-style Rx oversight system
You may also be interested in...
BIO’s Lucky Number 7? Follow-On Biologics Debate Offers Exclusivity Midpoint
A "split the difference" approach to determining how much exclusivity innovators would receive under a pathway establishing follow-on biologics would give brand products seven years of data exclusivity
BIO’s Lucky Number 7? Follow-On Biologics Debate Offers Exclusivity Midpoint
A "split the difference" approach to determining how much exclusivity innovators would receive under a pathway establishing follow-on biologics would give brand products seven years of data exclusivity
Generic Biologics May See Life After PDUFA; Senate Mark-Up Possible In May
Leadership of the Senate Health Committee remains committed to creating a pathway for follow-on biologics, despite the fact that language was not included in an omnibus FDA bill passed out of committee April 18